-
1
-
-
54249085533
-
Developments in the scientific and clinical understanding of gout
-
So A Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.
-
(2008)
Arthritis Res Ther
, vol.10
, pp. 221
-
-
So, A.1
-
3
-
-
79551559557
-
Gout
-
Neogi T Gout. N Engl J Med 2011, 64:443-452.
-
(2011)
N Engl J Med
, vol.64
, pp. 443-452
-
-
Neogi, T.1
-
4
-
-
84867405545
-
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
-
Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1848.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1839-1848
-
-
Schlesinger, N.1
Alten, R.E.2
Bardin, T.3
-
5
-
-
67449099218
-
Quality of life and disability in patients with treatment-failure gout
-
Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36:1041-1048.
-
(2009)
J Rheumatol
, vol.36
, pp. 1041-1048
-
-
Becker, M.A.1
Schumacher, H.R.2
Benjamin, K.L.3
-
6
-
-
65249136104
-
Perceptions of disease and health-related quality of life among patients with gout
-
Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology 2009, 48:582-586.
-
(2009)
Rheumatology
, vol.48
, pp. 582-586
-
-
Lee, S.J.1
Hirsch, J.D.2
Terkeltaub, R.3
-
7
-
-
84869180170
-
2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
-
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012, 64:1447-1461.
-
(2012)
Arthritis Care Res
, vol.64
, pp. 1447-1461
-
-
Khanna, D.1
Khanna, P.P.2
Fitzgerald, J.D.3
-
8
-
-
79551674574
-
Prevalence of contraindications and prescription of pharmacologic therapies for gout
-
Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163.
-
(2011)
Am J Med
, vol.124
, pp. 155-163
-
-
Keenan, R.T.1
O'Brien, W.R.2
Lee, K.H.3
-
9
-
-
77957688721
-
Canakimuab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study
-
So A, Meulemeester M Pikhlak A, et al. Canakimuab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 3064-3076
-
-
So, A.1
Meulemeester, M.2
Pikhlak, A.3
-
11
-
-
34548142983
-
Independent impact of gout on mortality and risk for coronary heart disease
-
Choi HK, Curhan G Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894-900.
-
(2007)
Circulation
, vol.116
, pp. 894-900
-
-
Choi, H.K.1
Curhan, G.2
-
12
-
-
33846998296
-
Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey
-
Choi HK, Ford ES, Li C, Curhan G Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57:109-115.
-
(2007)
Arthritis Rheum
, vol.57
, pp. 109-115
-
-
Choi, H.K.1
Ford, E.S.2
Li, C.3
Curhan, G.4
-
13
-
-
52949131004
-
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile
-
Choi H, Vera M, Krishman E Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008, 47:1567-1570.
-
(2008)
Rheumatology
, vol.47
, pp. 1567-1570
-
-
Choi, H.1
Vera, M.2
Krishman, E.3
-
14
-
-
56649112606
-
Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support
-
Colvine K, Kerr AJ, McLachlan A, et al. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. N Z Med J 2008, 121:73-81.
-
(2008)
N Z Med J
, vol.121
, pp. 73-81
-
-
Colvine, K.1
Kerr, A.J.2
McLachlan, A.3
-
15
-
-
55249099579
-
The role of hyperuricemia and gout in kidney and cardiovascular disease
-
Edwards NL The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75 (suppl 5):S13-S16.
-
(2008)
Cleve Clin J Med
, pp. S13-S16
-
-
Edwards, N.L.1
-
16
-
-
32944468985
-
Gout-associated uric acid crystals activate the NALP3 inflammasome
-
Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
-
(2006)
Nature
, vol.440
, pp. 237-241
-
-
Martinon, F.1
Petrilli, V.2
Mayor, A.3
-
17
-
-
78149484804
-
The pathogenesis of bone erosions in gouty arthritis
-
Schlesinger N, Thiele RG The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010, 69:1907-1912.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1907-1912
-
-
Schlesinger, N.1
Thiele, R.G.2
-
18
-
-
18644374105
-
Blocking IL-1 in systemic inflammation
-
Dinarello CA Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
-
(2005)
J Exp Med
, vol.201
, pp. 1355-1359
-
-
Dinarello, C.A.1
-
19
-
-
66049094734
-
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes
-
Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
-
(2009)
J Exp Med
, vol.206
, pp. 1029-1036
-
-
Lachmann, H.J.1
Lowe, P.2
Felix, S.D.3
-
20
-
-
46149100545
-
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
-
Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R67.
-
(2008)
Arthritis Res Ther
, vol.10
, pp. R67
-
-
Alten, R.1
Gram, H.2
Joosten, L.A.3
-
21
-
-
84955324434
-
-
Ilaris (canakinumab) Summary of Product Characteristics. Novartis Europharm Ltd, 2014.
-
(2014)
-
-
-
22
-
-
0017483654
-
Preliminary criteria for the classification of the acute arthritis of primary gout
-
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
-
(1977)
Arthritis Rheum
, vol.20
, pp. 895-900
-
-
Wallace, S.L.1
Robinson, H.2
Masi, A.T.3
-
23
-
-
84955245569
-
-
Novartis Pharma AG, data on file.
-
Novartis Pharma AG, data on file.
-
-
-
-
24
-
-
84955292709
-
Efficacy and safety of canakinumab versus triamcinolone acetonide in patients with gouty arthritis unable to use non-steroidal anti-inflammatory drugs and colchicine, and on stable urate-lowering therapy or unable to use urate-lowering therapy
-
Bardin T, So A, Alten R, et al. Efficacy and safety of canakinumab versus triamcinolone acetonide in patients with gouty arthritis unable to use non-steroidal anti-inflammatory drugs and colchicine, and on stable urate-lowering therapy or unable to use urate-lowering therapy. Arthritis Rheum 2012, 64(suppl):S811.
-
(2012)
Arthritis Rheum
, vol.64
, pp. S811
-
-
Bardin, T.1
So, A.2
Alten, R.3
-
25
-
-
84955293508
-
Long-term safety and efficacy of canakinumab vs triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine
-
Alten R, Schlesinger N, So A, et al. Long-term safety and efficacy of canakinumab vs triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine. Ann Rheum Dis 2014, 73(suppl 2):785.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 785
-
-
Alten, R.1
Schlesinger, N.2
So, A.3
-
26
-
-
84955298680
-
Canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: safety and efficacy results from long-term follow-up
-
Schlesinger N, Alten R, Bardin T, et al. Canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: safety and efficacy results from long-term follow-up. Arthritis Rheum 2014, 66(suppl):S66.
-
(2014)
Arthritis Rheum
, vol.66
, pp. S66
-
-
Schlesinger, N.1
Alten, R.2
Bardin, T.3
-
27
-
-
79953094557
-
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study
-
Schlesinger N, De Meulemeester MD, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011, 13:R53.
-
(2011)
Arthritis Res Ther
, vol.13
, pp. R53
-
-
Schlesinger, N.1
De Meulemeester, M.D.2
Pikhlak, A.3
|